<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1870-7203</journal-id>
<journal-title><![CDATA[Acta médica Grupo Ángeles]]></journal-title>
<abbrev-journal-title><![CDATA[Acta méd. Grupo Ángeles]]></abbrev-journal-title>
<issn>1870-7203</issn>
<publisher>
<publisher-name><![CDATA[Grupo Ángeles, Servicios de Salud]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1870-72032025000200143</article-id>
<article-id pub-id-type="doi">10.35366/119477</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Presente y futuro del tratamiento farmacológico de la obesidad]]></article-title>
<article-title xml:lang="en"><![CDATA[Present and future of pharmacological treatment of obesity]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Díaz Greene]]></surname>
<given-names><![CDATA[Enrique Juan]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Regules Silva]]></surname>
<given-names><![CDATA[Sonia de]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Santibañez Silva]]></surname>
<given-names><![CDATA[Violeta]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García Abarca]]></surname>
<given-names><![CDATA[Rebeca Saraí]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Angeles Pedregal  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Angeles Pedregal  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad del Valle de México Facultad de Medicina ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2025</year>
</pub-date>
<volume>23</volume>
<numero>2</numero>
<fpage>143</fpage>
<lpage>147</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1870-72032025000200143&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1870-72032025000200143&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1870-72032025000200143&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: La obesidad se define como &#8220;la acumulación anormal o excesiva de grasa que puede ser perjudicial para la salud&#8221;. Este es un problema de salud pública que ha ido aumentando su prevalencia en las últimas décadas, capaz de generar alteraciones metabólicas que aumentan la morbimortalidad. En la actualidad, la definición de obesidad que nos brinda la Organización Mundial de la Salud (OMS) habla de una acumulación excesiva o distribución anormal de grasa corporal que afecta la salud. Antes de 1990, se prescribían diferentes fármacos que buscaban tratar la obesidad, como el dinitrofenol, las anfetaminas, la fentermina, entre otros; lamentablemente estos fármacos carecían de estudios que sustentaran su eficacia y se retiraron del mercado. El tratamiento de la obesidad se debe abordar dependiendo del grado de obesidad y del paciente; las modificaciones en el estilo de vida y dieta son básicos dentro del tratamiento. Dentro de las nuevas terapéuticas utilizadas se encuentra el uso de retatrutide, un triple agonista de receptores GLP-1/GIP/GCG, cuyo efecto reduce la ingesta de alimentos y aumenta el gasto energético, promoviendo la reducción del peso junto con mejoría en los niveles de glucosa, no obstante, apenas se encuentra en fase 1B.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: Obesity is &#8220;the abnormal or excessive accumulation of fat that may be harmful to health&#8221;. This is a public health problem that has increased its prevalence in recent decades, causing metabolic alterations that raise morbidity and mortality. Currently, the World Health Organization&#8217;s definition of obesity refers to an excessive accumulation or abnormal distribution of body fat that affects health. Before 1990, various drugs were prescribed to treat obesity, such as dinitrophenol, amphetamines, and phentermine, among others; unfortunately, these drugs lacked studies supporting their effectiveness and were withdrawn from the market. The treatment of obesity should be approached based on the degree of obesity and the patient; lifestyle and diet modifications are essential in the treatment. Among the new therapies used is the use of retatrutide, a triple agonist of GLP-1/GIP/GCG receptors, whose effect reduces food intake and increases energy expenditure, promoting weight reduction along with improvement in glucose levels; however, it is still in phase 1B.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[orlistat]]></kwd>
<kwd lng="es"><![CDATA[liraglutida]]></kwd>
<kwd lng="es"><![CDATA[naltrexona/bupropión]]></kwd>
<kwd lng="es"><![CDATA[triple agonistas de receptores GLP-1/GIP/GCG]]></kwd>
<kwd lng="es"><![CDATA[índice de masa corporal]]></kwd>
<kwd lng="en"><![CDATA[orlistat]]></kwd>
<kwd lng="en"><![CDATA[liraglutide]]></kwd>
<kwd lng="en"><![CDATA[naltrexone/bupropion]]></kwd>
<kwd lng="en"><![CDATA[GLP-1/GIP/GCG receptor triple agonists]]></kwd>
<kwd lng="en"><![CDATA[body mass index]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meneses-Sierra]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ochoa-Martínez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Burciaga-Jiménez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Abordaje multidisciplinario del sobrepeso y la obesidad en adultos]]></article-title>
<source><![CDATA[Med Int Méx [Internet]]]></source>
<year>2023</year>
<volume>39</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>329-66</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perez-Campos]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mayoral]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Andrade]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mayoral]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[Huerta]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Canseco]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obesity subtypes, related biomarkers &amp; heterogeneity]]></article-title>
<source><![CDATA[Indian J Med Res [Internet]]]></source>
<year>2020</year>
<volume>151</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>11-21</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fitch]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Bays]]></surname>
<given-names><![CDATA[HE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obesity definition, diagnosis, bias, standard operating procedures (SOPs), and telehealth: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022]]></article-title>
<source><![CDATA[Obesity Pillars [Internet]]]></source>
<year>2022</year>
<volume>1</volume>
<page-range>100004</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pavía-López]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Alcocer-Gamba]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz-Gastelum]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
<name>
<surname><![CDATA[Mayorga-Butrón]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Mehta]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz-Aragón]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guía de práctica clínica mexicana para el diagnóstico y tratamiento de las dislipidemias y enfermedad cardiovascular aterosclerótica]]></article-title>
<source><![CDATA[Arch Cardiol Mex [Internet]]]></source>
<year>2022</year>
<volume>92</volume>
<page-range>1-62</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shamah-Levy]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Campos-Nonato]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Cuevas-Nasu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández-Barrera]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Morales-Ruán M del]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rivera-Dommarco]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sobrepeso y obesidad en población mexicana en condición de vulnerabilidad. Resultados de la Ensanut 100k]]></article-title>
<source><![CDATA[Salud Publica Mex [Internet]]]></source>
<year>2019</year>
<volume>61</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>852-65</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Campos-Nonato]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Galván-Valencia]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[en Nutr Pobl]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández-Barrera]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[en Epidem]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Oviedo-Solís]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalencia de obesidad y factores de riesgo asociados en adultos mexicanos: resultados de la Ensanut 2022]]></article-title>
<source><![CDATA[Salud Pública de México [Internet]]]></source>
<year>2023</year>
<volume>65</volume>
<page-range>S238-47</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The potential mechanisms of white adipose tissue browning: a novel target for the treatment of obesity]]></article-title>
<source><![CDATA[Nutr Hosp [Internet]]]></source>
<year>2022</year>
<volume>39</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>411-24</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosenstock]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Frias]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jastreboff]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Du]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Lou]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gurbuz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA]]></article-title>
<source><![CDATA[Lancet [Internet]]]></source>
<year>2023</year>
<volume>402</volume>
<numero>10401</numero>
<issue>10401</issue>
<page-range>529-44</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaufer-Horwitz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Carreto-Adán]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez-Hernández]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Perímetro de cuello y éxito del tratamiento de pacientes con obesidad: estudio de vida real]]></article-title>
<source><![CDATA[Gac Med Mex [Internet]]]></source>
<year>2019</year>
<volume>155</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>596-601</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaufer-Horwitz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez Hernández]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La obesidad: aspectos fisiopatológicos y clínicos]]></article-title>
<source><![CDATA[Inter Disciplina [Internet]]]></source>
<year>2022</year>
<volume>10</volume>
<numero>26</numero>
<issue>26</issue>
<page-range>147-75</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Benaiges]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Pedro-Botet]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Flores-Le Roux]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Climent]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Goday]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pasado, presente y futuro de la farmacoterapia para la obesidad]]></article-title>
<source><![CDATA[Clin Investig Arterioscler [Internet]]]></source>
<year>2017</year>
<volume>29</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>256-64</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salazar López]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La obesidad y su tratamiento a lo largo del tiempo]]></article-title>
<source><![CDATA[Rev Col Cirugía Plástica y Reconstructi [Internet]]]></source>
<year>2020</year>
<volume>26</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>71-5</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruiz-Cota]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bacardí-Gascón]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jiménez-Cruz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Historia, tendencias y causas de la obesidad en México]]></article-title>
<source><![CDATA[JONNPR [Internet]]]></source>
<year>2019</year>
<volume>4</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>737-45</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<source><![CDATA[DOF - Diario Oficial de la Federación [Internet]]]></source>
<year></year>
<publisher-name><![CDATA[Gob.mx]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kloock]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ziegler]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
<name>
<surname><![CDATA[Dischinger]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery?]]></article-title>
<source><![CDATA[Pharmacol Ther [Internet]]]></source>
<year>2023</year>
<volume>251</volume>
<numero>108549</numero>
<issue>108549</issue>
<page-range>108549</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dias]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Paredes]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ribeiro]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drugs involved in dyslipidemia and obesity treatment: Focus on adipose tissue]]></article-title>
<source><![CDATA[Int J Endocrinol [Internet]]]></source>
<year>2018</year>
<volume>2018</volume>
<page-range>2637418</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Genchi]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
<name>
<surname><![CDATA[Palma]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Sorice]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
<name>
<surname><![CDATA[D&#8217;Oria]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Caccioppoli]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Marrano]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacological modulation of adaptive thermogenesis: new clues for obesity management?]]></article-title>
<source><![CDATA[J Endocrinol Invest [Internet]]]></source>
<year>2023</year>
<volume>46</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2213-36</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
